Please assess the completion status of the following clinical trial:

Trial Title: Study of Transitioning From Alendronate to Denosumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal females 55 yrs or older~* Received alendronate therapy for osteoporosis for at least 6 months prior to entry into study~* Lumbar spine or total hip Bone Mineral Density (BMD) corresponding to T-score ≤ -2 and ≥ -4~Exclusion Criteria:~* Vitamin D deficiency~* Administration of intravenous bisphosphonate, or~* fluoride (except for dental treatment) or~* strontium ranelate~* Administration of Parathyroid Hormone (PTH) or Parathyroid Hormone (PTH) derivatives (eg; teriparatide) within the last year~* Administration of any bisphosphonate other than alendronate (ALN) within 1 year of screening

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- denosumab (Type: EXPERIMENTAL): None
- alendronate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).